JPMorgan Chase & Co. Lowers Medtronic (NYSE:MDT) Price Target to $100.00

Medtronic (NYSE:MDT) had its price objective dropped by investment analysts at JPMorgan Chase & Co. from $105.00 to $100.00 in a report issued on Wednesday,MarketScreener reports. The firm presently has a “neutral” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 3.99% from the company’s current price.

A number of other analysts have also commented on the stock. Sanford C. Bernstein lifted their price target on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Citigroup started coverage on Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target on the stock. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $111.05.

Medtronic Trading Down 0.3%

Shares of MDT traded down $0.25 during trading hours on Wednesday, reaching $96.16. 713,776 shares of the company traded hands, compared to its average volume of 8,479,095. Medtronic has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The company’s fifty day moving average price is $99.19 and its two-hundred day moving average price is $96.58. The company has a market capitalization of $123.28 billion, a price-to-earnings ratio of 25.92, a price-to-earnings-growth ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the previous year, the business posted $1.38 EPS. The company’s quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic will post 5.46 earnings per share for the current fiscal year.

Institutional Trading of Medtronic

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new stake in Medtronic during the 4th quarter valued at about $1,653,485,000. Capital Research Global Investors increased its position in shares of Medtronic by 12.6% during the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after acquiring an additional 3,880,174 shares during the period. Barclays PLC raised its stake in shares of Medtronic by 104.6% during the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after acquiring an additional 3,492,192 shares in the last quarter. Schroder Investment Management Group boosted its holdings in shares of Medtronic by 78.3% in the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after purchasing an additional 3,307,211 shares during the period. Finally, Guinness Asset Management LTD bought a new position in Medtronic in the third quarter worth approximately $275,556,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat and reiterated guidance — Medtronic reported $9.02B revenue and $1.36 non‑GAAP EPS (above estimates) and reaffirmed FY26 EPS guidance, which supports near‑term visibility. PR Newswire: Medtronic Q3 Results
• Positive Sentiment: Cardio & diabetes momentum — Cardiovascular revenue up double digits with Cardiac Ablation Solutions up ~80% (U.S. up 137%); diabetes also showed mid‑single digit growth — key organic drivers for revenue upside. PR Newswire: Segment Growth
• Positive Sentiment: Regulatory/commercial catalysts — FDA clearances and first U.S. Hugo robotic‑assisted surgery performed at Cleveland Clinic (plus Infuse bone graft OK for TLIF and MiniMed Flex submission), which expand addressable markets. PR Newswire: Hugo first U.S. case
• Positive Sentiment: Analyst bullishness — TD Cowen reiterated a Buy with a $119 PT, and Needham kept a Buy at $120 (small PT trims), signaling continued analyst conviction behind the recovery thesis. TipRanks: TD Cowen reiterates Buy
• Neutral Sentiment: Technicals & positioning — Market commentary points to a bullish reversal pattern and heavy institutional accumulation; useful context for momentum traders but not a fundamental driver. MarketBeat: Textbook reversal
• Negative Sentiment: Price‑target cut / neutral rating from Baird — Robert W. Baird trimmed its PT to $100 and moved to Neutral, which could cap upside for some investors. Benzinga: Baird PT cut
• Negative Sentiment: Margin pressure & rising costs — Reports note profit fell on higher costs and tariff impacts; margin compression is a near‑term risk even as revenue grows. WSJ: Profit falls despite higher revenue

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).